NLRP3 and atherosclerosis: Additionally, Tranilast effectively enhanced NLRP3 ubiquitination and reduced vascular inflammation and atherosclerosis in low-density lipoprotein receptor and apolipoprotein E-deficient mice (Chen et al., 2020).